NRAS mutations in primary and metastatic melanomas of Japanese patients

International Journal of Clinical Oncology

Volumn 19, Issue 3, 2014, Pages 544-548

  Uhara, Hisashi ^a   Ashida, Atsuko ^a   Koga, Hiroshi ^a   Ogawa, Eisaku ^a   Uchiyama, Aya ^a   Uchiyama, Ryuhei ^a   Hayashi, Koichi ^a   Kiniwa, Yukiko ^a   Okuyama, Ryuhei ^a  

^a SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Heterogeneity; MAPK pathway; MEK inhibitor; Melanoma; Molecular targeted therapy; NRAS

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; GUANOSINE TRIPHOSPHATASE; MEMBRANE PROTEIN; NRAS PROTEIN, HUMAN;

ACRAL MELANOMA; ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER PATIENT; CUTANEOUS MELANOMA; EXON; FEMALE; GENE MUTATION; GENE SEQUENCE; GENETIC HETEROGENEITY; GENOTYPE; HUMAN; JAPANESE (PEOPLE); MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTATIC MELANOMA; MOLECULARLY TARGETED THERAPY; NON CHRONIC SUN INDUCED DAMAGE MELANOMA; ONCOGENE N RAS; POLYMERASE CHAIN REACTION; PRIMARY TUMOR; PRIORITY JOURNAL; SANGER SEQUENCING; SIGNAL TRANSDUCTION; SUN EXPOSURE; ASIAN CONTINENTAL ANCESTRY GROUP; CAUCASIAN; GENETICS; MIDDLE AGED; MUTATION; PATHOLOGY; SKIN TUMOR; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; EUROPEAN CONTINENTAL ANCESTRY GROUP; EXONS; FEMALE; GTP PHOSPHOHYDROLASES; HUMANS; MALE; MELANOMA; MEMBRANE PROTEINS; MIDDLE AGED; MUTATION; SKIN NEOPLASMS;

EID: 84903277457     PISSN: 13419625     EISSN: 14377772     Source Type: Journal    
DOI: 10.1007/s10147-013-0573-2     Document Type: Article

References (20)

1. Roring M, Brummer T (2012) Aberrant b-raf signaling in human cancer - 10 years from bench to bedside. Crit Rev Oncog 17:97-121
2. Curtin JA, Fridlyand J, Kageshita T et al (2011) Distinct sets of genetic alterations in melanoma. N Engl J Med 353:2135-2147
3. Chapman PB, Hauschild A, Robert C et al (2011) Improved survival with vemurafenib in melanoma with braf v600e mutation. N Engl J Med 364:2507-2516
4. Goel VK, Lazar AJ, Warneke CL et al (2006) Examination of mutations in braf, nras, and pten in primary cutaneous melanoma. J Invest Dermatol 126:154-160 (Pubitemid 43336107)
5. Jakob JA, Bassett RL Jr, Ng CS et al (2012) Nras mutation status is an independent prognostic factor in metastatic melanoma. Cancer 118:4014-4023
6. Lee JH, Choi JW, Kim YS (2011) Frequencies of braf and nras mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis. Br J Dermatol 164: 776-784
7. Akslen LA, Angelini S, Straume O et al (2005) Braf and nras mutations are frequent in nodular melanoma but are not associated with tumor cell proliferation or patient survival. J Invest Dermatol 125:312-317 (Pubitemid 41648165)
8. Devitt B, Liu W, Salemi R et al (2011) Clinical outcome and pathological features associated with nras mutation in cutaneous melanoma. Pigment Cell Melanoma Res 24:666-672
9. Edlundh-Rose E, Egyhazi S, Omholt K et al (2006) Nras and braf mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing. Melanoma Res 16:471-478 (Pubitemid 44934704)
10. Ellerhorst JA, Greene VR, Ekmekcioglu S et al (2011) Clinical correlates of nras and braf mutations in primary human melanoma. Clin Cancer Res 17:229-235
11. Si L, Kong Y, Xu X et al (2012) Prevalence of braf v600e mutation in Chinese melanoma patients: large scale analysis of braf and nras mutations in a 432-case cohort. Eur J Cancer 48:94-100
12. Zhou QM, Li W, Zhang X et al (2012) The mutation profiles of common oncogenes involved in melanoma in southern china. J Invest Dermatol 132:1935-1937
13. Ascierto PA, Schadendorf D, Berking C et al (2013) Mek162 for patients with advanced melanoma harbouring nras or val600 braf mutations: a non-randomised, open-label phase 2 study. Lancet Oncol 14:249-256
14. Ashida A, Uhara H, Kiniwa Y et al (2012) Assessment of braf and kit mutations in Japanese melanoma patients. J Dermatol Sci 66:240-242
15. Colombino M, Capone M, Lissia A et al (2012) Braf/nras mutation frequencies among primary tumors and metastases in patients with melanoma. J Clin Oncol 30:2522-2529
16. Falchook GS, Lewis KD, Infante JR et al (2012) Activity of the oral mek inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. Lancet Oncol 13:782-789
17. Kirkwood JM, Bastholt L, Robert C et al (2012) Phase ii, openlabel, randomized trial of the mek1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma. Clin Cancer Res 18:555-567
18. Gerlinger M, Rowan AJ, Horswell S et al (2012) Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 366:883-892
19. Klein CA (2009) Parallel progression of primary tumours and metastases. Nat Rev Cancer 9:302-312
20. Solit DB, Garraway LA, Pratilas CA et al (2006) Braf mutation predicts sensitivity to mek inhibition. Nature 439:358-362 (Pubitemid 43128863)